Bone health in systemic lupus erythematosus

Current Rheumatology Reports

Volumn 11, Issue 3, 2009, Pages 177-184

  Panopalis, Pantelis ^a   Yazdany, Jinoos ^b  

^a MONTREAL GENERAL HOSPITAL   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ALFACALCIDOL; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCITRIOL; CALCIUM; CORTICOSTEROID; ESTROGEN; ETIDRONIC ACID; FULVESTRANT; PAMIDRONIC ACID; PLACEBO; PRASTERONE; PREDNISONE; RALOXIFENE; RISEDRONIC ACID; VITAMIN D;

ALCOHOL ABSTINENCE; BONE DENSITY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CORTICOSTEROID INDUCED OSTEOPOROSIS; DIET SUPPLEMENTATION; DOSE RESPONSE; DRUG EFFICACY; DRUG EXPOSURE; DRUG HALF LIFE; DRUG USE; EXERCISE; FRAGILITY FRACTURE; HIP FRACTURE; HORMONAL THERAPY; HUMAN; LIFESTYLE MODIFICATION; LOW DRUG DOSE; MONOTHERAPY; NONHUMAN; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; POSTMENOPAUSE OSTEOPOROSIS; PREVALENCE; PRIMARY PREVENTION; REVIEW; RISK FACTOR; SMOKING CESSATION; SPINE FRACTURE; SYSTEMIC LUPUS ERYTHEMATOSUS; VERTEBRA FRACTURE; ADOLESCENT; ADULT; BONE; CHILD; COMORBIDITY; FEMALE; LONGITUDINAL STUDY; MALE; PATHOPHYSIOLOGY;

ADOLESCENT; ADULT; BONE AND BONES; BONE DENSITY; CHILD; COMORBIDITY; FEMALE; HUMANS; LONGITUDINAL STUDIES; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; OSTEOPOROSIS; RISK FACTORS;

EID: 70349582576     PISSN: 15233774     EISSN: 15346307     Source Type: Journal    
DOI: 10.1007/s11926-009-0024-2     Document Type: Review

References (71)

1. World Health Organization: Prevention and management of osteoporosis: report of a WHO scientific group. In WHO Technical Report Series 921. Geneva, Switzerland: World Health Organization; 2000.
2. C. Lee R. Ramsey-Goldman 2005 Osteoporosis in systemic lupus erythematosus mechanisms Rheum Dis Clin North Am 31 363 385 15922151 10.1016/j.rdc.2005.01.004 (Pubitemid 40732494)
3. I.E. Bultink W.F. Lems P.J. Kostense, et al. 2005 Prevalence of and risk factors for low bone mineral density and vertebral fractures in patients with systemic lupus erythematosus Arthritis Rheum 52 2044 2050 15986345 10.1002/art.21110 (Pubitemid 40994328)
4. F. Formiga J.M. Nolla I. Moga D. Roig-Escofet 1996 Sequential study of bone mineral density in patients with systemic lupus erythematosus Ann Rheum Dis 55 857 8976648 10.1136/ard.55.11.857-a 1:STN:280:DyaK2s7jtV2qtA%3D%3D (Pubitemid 26392290)
5. M. Boyanov R. Robeva P. Popivanov 2003 Bone mineral density changes in women with systemic lupus erythematosus Clin Rheumatol 22 318 323 14579164 10.1007/s10067-003-0743-0 1:STN:280:DC%2BD3srgtV2gsA%3D%3D (Pubitemid 37483628)
6. A.A. Kalla A.B. Fataar S.J. Jessop L. Bewerunge 1993 Loss of trabecular bone mineral density in systemic lupus erythematosus Arthritis Rheum 36 1726 1734 8250992 10.1002/art.1780361212 1:STN:280:DyaK2c%2Fnt1ShsA%3D%3D (Pubitemid 23360013)
7. F. Formiga I. Moga J.M. Nolla, et al. 1995 Loss of bone mineral density in premenopausal women with systemic lupus erythematosus Ann Rheum Dis 54 274 276 7763104 10.1136/ard.54.4.274 1:STN:280:DyaK2M3otlersA%3D%3D
8. M. Petri 1995 Musculoskeletal complications of systemic lupus erythematosus in the Hopkins Lupus Cohort: an update Arthritis Care Res 8 137 145 7654797 10.1002/art.1790080305 1:STN:280:DyaK2MzotlChsw%3D%3D
9. Y. Kipen R. Buchbinder A. Forbes, et al. 1997 Prevalence of reduced bone mineral density in systemic lupus erythematosus and the role of steroids J Rheumatol 24 1922 1929 9330933 1:CAS:528:DyaK2sXmslyitb8%3D
10. L. Sinigaglia M. Varenna L. Binelli, et al. 1999 Determinants of bone mass in systemic lupus erythematosus: a cross sectional study on premenopausal women J Rheumatol 26 1280 1284 10381043 1:STN:280:DyaK1MzgvVOmsg%3D%3D
11. I.M. Gilboe T.K. Kvien G. Haugeberg G. Husby 2000 Bone mineral density in systemic lupus erythematosus: comparison with rheumatoid arthritis and healthy controls Ann Rheum Dis 59 110 115 10666165 10.1136/ard.59.2.110 1:STN:280:DC%2BD3c7ivFChug%3D%3D (Pubitemid 30305607)
12. H.P. Bhattoa P. Bettembuk A. Balogh, et al. 2002 Bone mineral density in women with systemic lupus erythematosus Clin Rheumatol 21 135 141 12086164 10.1007/s10067-002-8272-9 1:STN:280:DC%2BD38zktlOjtQ%3D%3D (Pubitemid 34649595)
13. K. Almehed H. Forsblad d'Elia G. Kvist, et al. 2007 Prevalence and risk factors of osteoporosis in female SLE patients-extended report Rheumatology (Oxford) 46 1185 1190 10.1093/rheumatology/kem105 1:STN:280: DC%2BD2sznsVSqtw%3D%3D (Pubitemid 47050627)
14. C. Lee O. Almagor D.D. Dunlop, et al. 2006 Disease damage and low bone mineral density: an analysis of women with systemic lupus erythematosus ever and never receiving corticosteroids Rheumatology (Oxford) 45 53 60 10.1093/rheumatology/kei079 1:CAS:528:DC%2BD2MXhtlagtbvO (Pubitemid 43033875)
15. C.C. Mok A. Mak K.M. Ma 2005 Bone mineral density in postmenopausal Chinese patients with systemic lupus erythematosus Lupus 14 106 112 15751814 10.1191/0961203305lu2039oa 1:STN:280:DC%2BD2M7itFelsw%3D%3D (Pubitemid 40327660)
16. J. Teichmann U. Lange H. Stracke, et al. 1999 Bone metabolism and bone mineral density of systemic lupus erythematosus at the time of diagnosis Rheumatol Int 18 137 140 10220833 10.1007/s002960050072 1:STN:280: DyaK1M3jslWrsA%3D%3D
17. A.A. Kalla T.J. van Wyk Kotze O.L. Meyers 1992 Metacarpal bone mass in systemic lupus erythematosus Clin Rheumatol 11 475 482 1486735 10.1007/BF02283101 1:STN:280:DyaK3s7jslGgsw%3D%3D (Pubitemid 23028022)
18. A. Angeli G. Guglielmi A. Dovio, et al. 2006 High prevalence of asymptomatic vertebral fractures in post-menopausal women receiving chronic glucocorticoid therapy: a cross-sectional outpatient study Bone 39 253 259 16574519 10.1016/j.bone.2006.02.005 1:CAS:528:DC%2BD28Xls1ejt7s%3D (Pubitemid 43870263)
19. S. Uaratanawong U. Deesomchok N. Hiransuttikul S. Uaratanawong 2004 Four years follow-up of bone mineral density change in premenopausal women with systemic lupus erythematosus J Med Assoc Thai 87 1374 1379 15825716
20. S. Uaratanawong U. Deesomchoke S. Lertmaharit S. Uaratanawong 2003 Bone mineral density in premenopausal women with systemic lupus erythematosus J Rheumatol 30 2365 2368 14677178
21. I. Korczowska A. Olewicz-Gawlik P. Hrycaj J. Lacki 2003 The effect of long-term glucocorticoids on bone metabolism in systemic lupus erythematosus patients: the prevalence of its anti-inflammatory action upon bone resorption Yale J Biol Med 76 45 54 15369631 1:CAS:528:DC%2BD2MXps1OksA%3D%3D
22. C.S. Yee N. Crabtree J. Skan, et al. 2005 Prevalence and predictors of fragility fractures in systemic lupus erythematosus Ann Rheum Dis 64 111 113 15608308 10.1136/ard.2003.018127 (Pubitemid 40075285)
23. R.B. de Deus A.C. Ferreira G.M. Kirsztajn I.P. Heilberg 2003 Osteopenia in patients with glomerular diseases requiring long-term corticosteroid therapy Nephron Clin Pract 94 c69 c74 12902633 10.1159/000072023
24. I.B. Coimbra L.T. Costallat 2003 Bone mineral density in systemic lupus erythematosus and its relation to age at disease onset, plasmatic estradiol and immunosuppressive therapy Joint Bone Spine 70 40 45 12639616 10.1016/S1297-319X(02)00009-X (Pubitemid 36350411)
25. A. Becker R. Fischer W.A. Scherbaum M. Schneider 2001 Osteoporosis screening in systemic lupus erythematosus: impact of disease duration and organ damage Lupus 10 809 814 11789491 10.1177/096120330101001108 1:STN:280: DC%2BD38%2FmtlOmsA%3D%3D
26. H.P. Bhattoa E. Kiss P. Bettembuk A. Balogh 2001 Bone mineral density, biochemical markers of bone turnover, and hormonal status in men with systemic lupus erythematosus Rheumatol Int 21 97 102 11765229 10.1007/s00296-001-0149-8 1:CAS:528:DC%2BD38XislCgtg%3D%3D (Pubitemid 33071190)
27. S. Lakshminarayanan S. Walsh M. Mohanraj N. Rothfield 2001 Factors associated with low bone mineral density in female patients with systemic lupus erythematosus J Rheumatol 28 102 108 11196509 1:STN:280:DC%2BD3M7jtFOqsw%3D%3D
28. D. Jardinet C. Lefèbvre G. Depresseux, et al. 2000 Longitudinal analysis of bone mineral density in pre-menopausal female systemic lupus erythematosus patients: deleterious role of glucocorticoid therapy at the lumbar spine Rheumatology (Oxford) 39 389 392 10.1093/rheumatology/39.4.389 1:CAS:528:DC%2BD3cXkt1CmsLo%3D
29. E.K. Li L.S. Tam R.P. Young, et al. 1998 Loss of bone mineral density in Chinese pre-menopausal women with systemic lupus erythematosus treated with corticosteroids Br J Rheumatol 37 405 410 9619891 10.1093/rheumatology/37.4.405 1:STN:280:DyaK1c3otFWqsg%3D%3D
30. F. Formiga J.M. Nolla F. Mitjavila, et al. 1996 Bone mineral density and hormonal status in men with systemic lupus erythematosus Lupus 5 623 626 9116708 10.1177/096120339600500612 1:STN:280:DyaK2s7lsl2gsw%3D%3D (Pubitemid 27035735)
31. F.A. Houssiau C. Lefèbvre G. Depresseux, et al. 1996 Trabecular and cortical bone loss in systemic lupus erythematosus Br J Rheumatol 35 244 247 8620299 10.1093/rheumatology/35.3.244 1:STN:280:DyaK287psVWrsQ%3D%3D
32. V.B. Dhillon M.C. Davies M.L. Hall, et al. 1990 Assessment of the effect of oral corticosteroids on bone mineral density in systemic lupus erythematosus: a preliminary study with dual energy x ray absorptiometry Ann Rheum Dis 49 624 626 2396869 10.1136/ard.49.8.624 1:STN:280:DyaK3cznt1OhsA%3D%3D
33. K. Redlich S. Ziegler H.P. Kiener, et al. 2000 Bone mineral density and biochemical parameters of bone metabolism in female patients with systemic lupus erythematosus Ann Rheum Dis 59 308 310 10733481 10.1136/ard.59.4.308 1:STN:280:DC%2BD3c7pslylsw%3D%3D (Pubitemid 30305576)
34. M. Hansen P. Halberg G. Kollerup, et al. 1998 Bone metabolism in patients with systemic lupus erythematosus. Effect of disease activity and glucocorticoid treatment Scand J Rheumatol 27 197 206 9645415 10.1080/030097498440813 1:STN:280:DyaK1czgslehsA%3D%3D (Pubitemid 28267112)
35. C.C. Mok S.K. Ying C.H. To K.M. Ma 2008 Bone mineral density and body composition in men with systemic lupus erythematosus: a case control study Bone 43 327 331 18515206 10.1016/j.bone.2008.04.003
36. V. Lilleby 2007 Bone status in juvenile systemic lupus erythematosus Lupus 16 580 586 17711892 10.1177/0961203307079040 1:STN:280: DC%2BD2svpt12ktg%3D%3D (Pubitemid 47359992)
37. V. Lilleby G. Lien K. Frey Froslie, et al. 2005 Frequency of osteopenia in children and young adults with childhood-onset systemic lupus erythematosus Arthritis Rheum 52 2051 2059 15986346 10.1002/art.21115 (Pubitemid 40994329)
38. S. Compeyrot-Lacassagne P.N. Tyrrell K. Atenafu, et al. 2007 Prevalence and etiology of low bone mineral density in juvenile systemic lupus erythematosus Arthritis Rheum 56 1966 1973 17530722 10.1002/art.22691
39. R. Ramsey-Goldman J.E. Dunn C.F. Huang, et al. 1999 Frequency of fractures in women with systemic lupus erythematosus: comparison with United States population data Arthritis Rheum 42 882 890 10323443 10.1002/1529- 0131(199905)42:5<882::AID-ANR6>3.0.CO;2-C 1:STN:280:DyaK1M3lsFShsA%3D%3D (Pubitemid 29214998)
40. C. Lee O. Almagor D.D. Dunlop, et al. 2007 Self-reported fractures and associated factors in women with systemic lupus erythematosus J Rheumatol 34 2018 2023 17787041
41. V.Z. Borba P.G. Matos P.R. da Silva Viana, et al. 2005 High prevalence of vertebral deformity in premenopausal systemic lupus erythematosus patients Lupus 14 529 533 16130509 10.1191/0961203305lu2154oa 1:STN:280: DC%2BD2Mvmtlansw%3D%3D (Pubitemid 41161084)
42. R.R. McLean P.F. Jacques J. Selhub, et al. 2004 Homocysteine as a predictive factor for hip fracture in older persons N Engl J Med 350 2042 2049 15141042 10.1056/NEJMoa032739 1:CAS:528:DC%2BD2cXktVeis7g%3D (Pubitemid 38596555)
43. E.Y. Rhew C. Lee P. Eksarko, et al. 2008 Homocysteine, bone mineral density, and fracture risk over 2 years of followup in women with and without systemic lupus erythematosus J Rheumatol 35 230 236 18203323
44. F. Pons P. Peris N. Guañabens, et al. 1995 The effect of systemic lupus erythematosus and long-term steroid therapy on bone mass in pre-menopausal women Br J Rheumatol 34 742 746 7551659 10.1093/rheumatology/34.8.742 1:STN:280:DyaK28%2FjsF2iuw%3D%3D
45. M.J. Neff 2004 ACOG releases guidelines for clinical management of osteoporosis Am Fam Physician 69 1558 15053420
46. American College of Rheumatology Ad Hoc Committee on Glucocorticoid- Induced Osteoporosis Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. Arthritis Rheum 2001, 44:1496-1503.
47. J.P. Brown R.G. Josse 2002 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada CMAJ 167 10Suppl S1 34 12427685
48. I. Lambrinoudaki D.T. Chan C.S. Lau, et al. 2000 Effect of calcitriol on bone mineral density in premenopausal Chinese women taking chronic steroid therapy. A randomized, double blind, placebo controlled study J Rheumatol 27 1759 1765 10914864 1:CAS:528:DC%2BD3cXltlKqsLY%3D
49. A.W. Kung T.M. Chan C.S. Lau, et al. 1999 Osteopenia in young hypogonadal women with systemic lupus erythematosus receiving chronic steroid therapy: a randomized controlled trial comparing calcitriol and hormonal replacement therapy Rheumatology (Oxford) 38 1239 1244 10.1093/rheumatology/38.12.1239 1:CAS:528:DC%2BD3cXks1OnsQ%3D%3D
50. P. Lakatos Z. Nagy L. Kiss, et al. 2000 Prevention of corticosteroid-induced osteoporosis by alfacalcidol Z Rheumatol 59 Suppl1 48 52 10769437 10.1007/s003930070040
51. H.C. Chong S.S. Chee E.M. Goh, et al. 2007 Dietary calcium and bone mineral density in premenopausal women with systemic lupus erythematosus Clin Rheumatol 26 182 185 16565892 10.1007/s10067-006-0258-6 1:STN:280: DC%2BD28jks1CisQ%3D%3D (Pubitemid 46020240)
52. H.P. Bhattoa P. Bettembuk A. Balogh, et al. 2004 The effect of 1-year transdermal estrogen replacement therapy on bone mineral density and biochemical markers of bone turnover in osteopenic postmenopausal systemic lupus erythematosus patients: a randomized, double-blind, placebo-controlled trial Osteoporos Int 15 396 404 14676992 10.1007/s00198-003-1566-1 1:CAS:528:DC%2BD2cXjt1Gmtb4%3D
53. J.E. Manson J. Hsia K.C. Johnson, et al. 2003 Estrogen plus progestin and the risk of coronary heart disease N Engl J Med 349 523 534 12904517 10.1056/NEJMoa030808 1:CAS:528:DC%2BD3sXmtFCmsr0%3D (Pubitemid 36951364)
54. C.C. Mok C.H. To A. Mak K.M. Ma 2005 Raloxifene for postmenopausal women with systemic lupus erythematosus: a pilot randomized controlled study Arthritis Rheum 52 3997 4002 16320346 10.1002/art.21477 1:CAS:528:DC%2BD28XjvF2hug%3D%3D (Pubitemid 41798239)
55. N.I. Abdou V. Rider C. Greenwell, et al. 2008 Fulvestrant (Faslodex), an estrogen selective receptor downregulator, in therapy of women with systemic lupus erythematosus. Clinical, serologic, bone density, and T cell activation marker studies: a double-blind placebo-controlled trial J Rheumatol 35 797 18381791 1:CAS:528:DC%2BD1cXntVOmurw%3D
56. J. Sanchez-Guerrero H.E. Fragoso-Loyo C.M. Neuwelt, et al. 2008 Effects of prasterone on bone mineral density in women with active systemic lupus erythematosus receiving chronic glucocorticoid therapy J Rheumatol 35 1567 1575 18634158 1:CAS:528:DC%2BD1cXhtV2lsr7K
57. A. Cranney V. Welch J.D. Adachi, et al. 2000 Calcitonin for the treatment and prevention of corticosteroid-induced osteoporosis Cochrane Database Syst Rev 2 CD001983 10796457
58. U.A. Liberman S.R. Weiss J. Broll, et al. 1995 Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group N Engl J Med 333 1437 1443 7477143 10.1056/NEJM199511303332201 1:CAS:528:DyaK28XkslehtA%3D%3D
59. D.M. Black S.R. Cummings D.B. Karpf, et al. 1996 Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group Lancet 348 1535 1541 8950879 10.1016/S0140-6736(96)07088-2 1:CAS:528:DyaK2sXisFCktQ%3D%3D (Pubitemid 26411651)
60. S.T. Harris N.B. Watts H.K. Genant, et al. 1999 Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group JAMA 282 1344 1352 10527181 10.1001/jama.282.14.1344 1:CAS:528:DyaK1MXmvFansr0%3D (Pubitemid 29483192)
61. M.R. McClung P. Geusens P.D. Miller, et al. 2001 Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group N Engl J Med 344 333 340 11172164 10.1056/NEJM200102013440503 1:CAS:528:DC%2BD3MXht1Wlu7g%3D (Pubitemid 32107641)
62. J.D. Adachi W.G. Bensen J. Brown, et al. 1997 Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis N Engl J Med 337 382 387 9241127 10.1056/NEJM199708073370603 1:CAS:528:DyaK2sXls1elu7Y%3D (Pubitemid 27328368)
63. C. Roux P. Oriente R. Laan, et al. 1998 Randomized trial of effect of cyclical etidronate in the prevention of corticosteroid-induced bone loss. Ciblos Study Group J Clin Endocrinol Metab 83 1128 1133 9543129 10.1210/jc.83.4.1128 1:CAS:528:DyaK1cXitlynsLc%3D (Pubitemid 28496380)
64. K.G. Saag R. Emkey T.J. Schnitzer, et al. 1998 Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group N Engl J Med 339 292 299 9682041 10.1056/NEJM199807303390502 1:CAS:528:DyaK1cXlsVOitr4%3D (Pubitemid 28366417)
65. J.D. Adachi K.G. Saag P.D. Delmas, et al. 2001 Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial Arthritis Rheum 44 202 211 11212161 10.1002/1529-0131(200101)44:1<202::AID- ANR27>3.0.CO;2-W 1:CAS:528:DC%2BD3MXht1yiu7o%3D (Pubitemid 32113136)
66. E. Shane V. Addesso P.B. Namerow, et al. 2004 Alendronate versus calcitriol for the prevention of bone loss after cardiac transplantation N Engl J Med 350 767 776 14973216 10.1056/NEJMoa035617 1:CAS:528:DC%2BD2cXhsVems74%3D (Pubitemid 38209646)
67. R. Eastell J.P. Devogelaer N.F. Peel, et al. 2000 Prevention of bone loss with risedronate in glucocorticoid-treated rheumatoid arthritis patients Osteoporos Int 11 331 337 10928223 10.1007/s001980070122 1:CAS:528: DC%2BD3cXmtVakt74%3D (Pubitemid 30417186)
68. S. Cohen R.M. Levy M. Keller, et al. 1999 Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study Arthritis Rheum 42 2309 2318 10555025 10.1002/1529-0131(199911)42:11<2309::AID-ANR8>3.0.CO;2-K 1:CAS:528:DyaK1MXnvVShsLs%3D (Pubitemid 30333410)
69. D.M. Reid R.A. Hughes R.F. Laan, et al. 2000 Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study J Bone Miner Res 15 1006 1013 10841169 10.1359/jbmr.2000.15.6. 1006 1:CAS:528:DC%2BD3cXktFKhtbs%3D
70. A. Nzeusseu Toukap G. Depresseux J.P. Devogelaer F.A. Houssiau 2005 Oral pamidronate prevents high-dose glucocorticoid-induced lumbar spine bone loss in premenopausal connective tissue disease (mainly lupus) patients Lupus 14 517 520 16130506 10.1191/0961203305lu2149oa 1:STN:280:DC%2BD2Mvmtlagug%3D%3D (Pubitemid 41161081)
71. J.P. Buyon M.A. Petri M.Y. Kim, et al. 2005 The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trial Ann Intern Med 142 12Pt1 953 962 15968009 1:CAS:528:DC%2BD2MXmt1ertb0%3D